David Sans
| David Sans | |
|---|---|
 DavidSans1.jpg | |
| Born | |
| 🏳️ Nationality | American |
| 💼 Occupation | Healthcare Investment Banking |
| Twitter= | |
David Sans, FAARM, Ph.D., M.B.A., is a Chemical Engineer with a PhD in Chemometrics and Artificial Intelligence from the labs of Dr. Stoessel at the ETH in Zurich and a Board Certification in Cell Therapies from Mount Sinai.[1][2][3]
David is fully licensed in Healthcare Investment Banking with FINRA Series 7, 63, 15 and 55. David has over 12 years of Healthcare Investment Banking experience delivering the full suite of investment banking advisory services, including M&A, project finance, capital raising and special situations.
Since 2008, David’s clients executed more than 100 Healthcare Investment Banking transactions delivering exceptional services for financial institutions, healthcare institutional investors and strategic partners.
Among others, David originated the AI Pathology platform at Mount Sinai Hospital in New York in 2012 and sold it to Philips in 2021. David’s IPOs include Annovis Bio with a $600 m value creation from its $10 m IPO in December 2020.
David served as VP of Finance and Investment Strategy at ImClone Systems reporting to the CEO and the Board of Directors and as Managing Director of Healthcare Banking at ThinkEquity. David started as Sr. Medical Scientist at Novartis during the launch of Glivec® (Imatinib) in Switzerland, Dir. of Market Analytics at Pfizer during the launch or Rebif® (interferon beta-1a for MS) and Macugen.
References[edit]
- ↑ "David Sans Discusses Axonal Transport and How It Could Help Patients with Alzheimer's". www.accesswire.com. Retrieved 2021-12-22.
- ↑ Hunter, Caroline (2021-11-18). "David Sans on How Cell Therapy Startups Can Help Streamline Healthcare as We Know It". EIN Presswire. Retrieved 2021-12-22.
- ↑ "How David Sans of New York Used His Chemical Engineering Background to Become a Successful Investor". www.accesswire.com. Retrieved 2021-12-22.
